CAR T-cell therapy has good prospects for moving into the field of solid tumors, suggests Michel Sadelain, MD, PhD, of the Memorial Sloan Kettering Cancer Center, New York, NY, at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany. With adjustments, particularly for the tumor microenvironments, Dr Sadelain believes it will be possible to use CAR-T technology in the solid setting.
